{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T14:28:05Z","timestamp":1780496885485,"version":"3.54.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,3]]},"DOI":"10.7759\/cureus.110178","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T13:59:06Z","timestamp":1780495146000},"source":"Crossref","is-referenced-by-count":0,"title":["Comparative Positioning of Orforglipron Among Selected GLP-1 Receptor Agonist Benchmarks: A Narrative Review"],"prefix":"10.7759","author":[{"given":"Jos\u00e9","family":"Castro-Gamboa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeaustin","family":"Mora-Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebasti\u00e1n","family":"Arguedas-Chac\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Zavaleta-Monestel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2014879117","article-title":"Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist","volume":"117","author":"Kawai T","year":"2020","unstructured":"Kawai T, Sun B, Yoshino H, et al.. Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist. Proc Natl Acad Sci USA. 2020, 117:29959-67. 10.1073\/pnas.2014879117","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms27031409","article-title":"Orforglipron: A comprehensive review of an oral small-molecule GLP-1 receptor agonist for obesity and type 2 diabetes","volume":"27","author":"Kansakar U","year":"2026","unstructured":"Kansakar U, Jankauskas SS, Pande S, Mone P, Varzideh F, Santulli G. Orforglipron: A comprehensive review of an oral small-molecule GLP-1 receptor agonist for obesity and type 2 diabetes. Int J Mol Sci. 2026, 27:1409. 10.3390\/ijms27031409","journal-title":"Int J Mol Sci"},{"key":"ref3","unstructured":"DailyMed. FOUNDAYO - orforglipron tablet, film coated. (2026). Accessed: April 24, 2026: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15184","article-title":"Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: a phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants","volume":"25","author":"Pratt E","year":"2023","unstructured":"Pratt E, Ma X, Liu R, et al.. Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: a phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants. Diabetes Obes Metab. 2023, 25:2634-41. 10.1111\/dom.15184","journal-title":"Diabetes Obes Metab"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15150","article-title":"Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: a phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes","volume":"25","author":"Pratt E","year":"2023","unstructured":"Pratt E, Ma X, Liu R, et al.. Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: a phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes. Diabetes Obes Metab. 2023, 25:2642-9. 10.1111\/dom.15150","journal-title":"Diabetes Obes Metab"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-024-01554-1","article-title":"Effect of food consumption on the pharmacokinetics, safety, and tolerability of once-daily orally administered Orforglipron (LY3502970), a non-peptide GLP-1 receptor agonist","volume":"15","author":"Ma X","year":"2024","unstructured":"Ma X, Liu R, Pratt EJ, Benson CT, Bhattachar SN, Sloop KW. Effect of food consumption on the pharmacokinetics, safety, and tolerability of once-daily orally administered Orforglipron (LY3502970), a non-peptide GLP-1 receptor agonist. Diabetes Ther. 2024, 15:819-32. 10.1007\/s13300-024-01554-1","journal-title":"Diabetes Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01302-8","article-title":"Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study","volume":"402","author":"Frias JP","year":"2023","unstructured":"Frias JP, Hsia S, Eyde S, et al.. Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. Lancet. 2023, 402:472-83. 10.1016\/S0140-6736(23)01302-8","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(26)00202-3","article-title":"Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE- 3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial","volume":"407","author":"Rosenstock J","year":"2026","unstructured":"Rosenstock J, Yabe D, Cox D, et al.. Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE- 3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial. Lancet. 2026, 407:1147-60. 10.1016\/S0140-6736(26)00202-3","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adp5765","article-title":"The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron","volume":"16","author":"Sloop KW","year":"2024","unstructured":"Sloop KW, Cox AL, Wainscott DB, et al.. The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron. Sci Transl Med. 2024, 16:eadp5765. 10.1126\/scitranslmed.adp5765","journal-title":"Sci Transl Med"},{"key":"ref10","unstructured":"DailyMed. RYBELSUS - oral semaglutide tablet. (2026). Accessed: April 24, 2026: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98&utm_source=chatgpt.com."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s41073-019-0064-8","article-title":"SANRA-a scale for the quality assessment of narrative review articles","volume":"4","author":"Baethge C","year":"2019","unstructured":"Baethge C, Goldbeck-Wood S, Mertens S. SANRA-a scale for the quality assessment of narrative review articles. Res Integr Peer Rev. 2019, 4:5. 10.1186\/s41073-019-0064-8","journal-title":"Res Integr Peer Rev"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1594","article-title":"Disposition and absolute bioavailability of orally administered Orforglipron in healthy participants","volume":"15","author":"Morse BL","year":"2026","unstructured":"Morse BL, Bhattachar S, Ma X, Coutant DE, Czeskis B, Nicoll C, Cassidy KC. Disposition and absolute bioavailability of orally administered Orforglipron in healthy participants. Clin Pharmacol Drug Dev. 2026, 15:e1594. 10.1002\/cpdd.1594","journal-title":"Clin Pharmacol Drug Dev"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.70157","article-title":"A phase 1 single and multiple ascending dose study of orforglipron in Japanese participants with type 2 diabetes","volume":"17","author":"Ohwaki K","year":"2026","unstructured":"Ohwaki K, Nakamura C, Nasu R, Takenouchi K, Hirase T. A phase 1 single and multiple ascending dose study of orforglipron in Japanese participants with type 2 diabetes. J Diabetes Investig. 2026, 17:205-13. 10.1111\/jdi.70157","journal-title":"J Diabetes Investig"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-025-02781-x","article-title":"Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes","volume":"24","author":"Wharton S","year":"2025","unstructured":"Wharton S, Rosenstock J, Konige M, et al.. Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes. Cardiovasc Diabetol. 2025, 24:240. 10.1186\/s12933-025-02781-x","journal-title":"Cardiovasc Diabetol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70022","article-title":"Orforglipron, an oral non-peptide glucagon-like peptide-1 receptor agonist, improves markers of \u03b2-cell function and insulin sensitivity in type 2 diabetes","volume":"27","author":"Rosenstock J","year":"2025","unstructured":"Rosenstock J, Robins DA, Duffin KL, et al.. Orforglipron, an oral non-peptide glucagon-like peptide-1 receptor agonist, improves markers of \u03b2-cell function and insulin sensitivity in type 2 diabetes. Diabetes Obes Metab. 2025, 27:6314-22. 10.1111\/dom.70022","journal-title":"Diabetes Obes Metab"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2302392","article-title":"Daily oral GLP-1 receptor agonist Orforglipron for adults with obesity","volume":"389","author":"Wharton S","year":"2023","unstructured":"Wharton S, Blevins T, Connery L, et al.. Daily oral GLP-1 receptor agonist Orforglipron for adults with obesity. N Engl J Med. 2023, 389:877-88. 10.1056\/NEJMoa2302392","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2511774","article-title":"Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment","volume":"393","author":"Wharton S","year":"2025","unstructured":"Wharton S, Aronne LJ, Stefanski A, et al.. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N Engl J Med. 2025, 393:1796-806. 10.1056\/NEJMoa2511774","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2505669","article-title":"Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes","volume":"393","author":"Rosenstock J","year":"2025","unstructured":"Rosenstock J, Hsia S, Nevarez Ruiz L, et al.. Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes. N Engl J Med. 2025, 393:1065-76. 10.1056\/NEJMoa2505669","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)02165-8","article-title":"Orforglipron, an oral small-molecule GLP-1 receptor agonist for the treatment of obesity in people with type 2 diabetes (ATTAIN- 2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial","volume":"406","author":"Horn DB","year":"2025","unstructured":"Horn DB, Ryan DH, Kis SG, et al.. Orforglipron, an oral small-molecule GLP-1 receptor agonist for the treatment of obesity in people with type 2 diabetes (ATTAIN- 2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. Lancet. 2025, 406:2927-44. 10.1016\/S0140-6736(25)02165-8","journal-title":"Lancet"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1097\/CRD.0000000000001139","article-title":"Orforglipron: A novel oral GLP-1 agonist for the treatment of obesity and diabetes","author":"Pillai AA","year":"2025","unstructured":"Pillai AA, Sharma AM, Krayem H, Frishman WH, Aronow WS. Orforglipron: A novel oral GLP-1 agonist for the treatment of obesity and diabetes. Cardiol Rev. 2025, 10.1097\/CRD.0000000000001139","journal-title":"Cardiol Rev"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1646956","article-title":"The efficacy and safety of danuglipron and orforglipron in patients with type 2 diabetes and obesity: a systematic review and meta-analysis","volume":"16","author":"Zhou J","year":"2025","unstructured":"Zhou J, Wang F, Li S. The efficacy and safety of danuglipron and orforglipron in patients with type 2 diabetes and obesity: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2025, 16:1646956. 10.3389\/fendo.2025.1646956","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.70134","article-title":"Efficacy and safety of Orforglipron in obese adults with or without diabetes: a systematic review and meta-analysis","volume":"8","author":"Pandey RK","year":"2025","unstructured":"Pandey RK, Jan M, Mohammad A, et al.. Efficacy and safety of Orforglipron in obese adults with or without diabetes: a systematic review and meta-analysis. Endocrinol Diabetes Metab. 2025, 8:e70134. 10.1002\/edm2.70134","journal-title":"Endocrinol Diabetes Metab"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2021.102","article-title":"Peptidyl and non-peptidyl oral glucagon-like peptide-1 receptor agonists","volume":"36","author":"Choe HJ","year":"2021","unstructured":"Choe HJ, Cho YM. Peptidyl and non-peptidyl oral glucagon-like peptide-1 receptor agonists. Endocrinol Metab (Seoul). 2021, 36:22-9. 10.3803\/EnM.2021.102","journal-title":"Endocrinol Metab (Seoul)"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000046671","article-title":"Gastrointestinal side effects of the non-peptide GLP-1 receptor agonists: a systematic review and meta-analysis","volume":"104","author":"Bhattarai HB","year":"2025","unstructured":"Bhattarai HB, Paudel BS, Parajuli SR, et al.. Gastrointestinal side effects of the non-peptide GLP-1 receptor agonists: a systematic review and meta-analysis. Medicine (Baltimore). 2025, 104:e46671. 10.1097\/MD.0000000000046671","journal-title":"Medicine (Baltimore)"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2023.155710","article-title":"Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials","volume":"149","author":"Karakasis P","year":"2023","unstructured":"Karakasis P, Patoulias D, Pamporis K, et al.. Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials. Metabolism. 2023, 149:155710. 10.1016\/j.metabol.2023.155710","journal-title":"Metabolism"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1002\/osp4.743","article-title":"Orforglipron, a novel non-peptide oral daily glucagon-like peptide-1 receptor agonist as an anti-obesity medicine: a systematic review and meta-analysis","volume":"10","author":"Dutta D","year":"2024","unstructured":"Dutta D, Nagendra L, Anne B, Kumar M, Sharma M, Kamrul-Hasan AB. Orforglipron, a novel non-peptide oral daily glucagon-like peptide-1 receptor agonist as an anti-obesity medicine: a systematic review and meta-analysis. Obes Sci Pract. 2024, 10:e743. 10.1002\/osp4.743","journal-title":"Obes Sci Pract"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.20945\/2359-4292-2023-0469","article-title":"Effects of once-daily oral orforglipron on weight and metabolic markers: a systematic review and meta-analysis of randomized controlled trials","volume":"68","author":"L\u00fctkemeyer C","year":"2024","unstructured":"L\u00fctkemeyer C, Pasqualotto E, Ferreira RO, et al.. Effects of once-daily oral orforglipron on weight and metabolic markers: a systematic review and meta-analysis of randomized controlled trials. Arch Endocrinol Metab. 2024, 68:e230469. 10.20945\/2359-4292-2023-0469","journal-title":"Arch Endocrinol Metab"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.102018","article-title":"Comparative efficacy and safety of different Orforglipron doses in patients with type 2 diabetes mellitus and obesity: a systematic review and network meta-analysis","volume":"18","author":"Tantoush M","year":"2026","unstructured":"Tantoush M, Almaghrabi Y, Abusbaeh A, et al.. Comparative efficacy and safety of different Orforglipron doses in patients with type 2 diabetes mellitus and obesity: a systematic review and network meta-analysis. Cureus. 2026, 18:e102018. 10.7759\/cureus.102018","journal-title":"Cureus"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.56305\/001c.132255","article-title":"Current insights, advantages and challenges of small molecule glucagon-like peptide 1 receptor agonists: a scoping review","volume":"4","author":"Luna Ceron E","year":"2025","unstructured":"Luna Ceron E, Reddy SD, Kattamuri L, Muvva DM, Chozet L, Bright T. Current insights, advantages and challenges of small molecule glucagon-like peptide 1 receptor agonists: a scoping review. J Brown Hosp Med. 2025, 4:19-32. 10.56305\/001c.132255","journal-title":"J Brown Hosp Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1186\/s40842-025-00270-4","article-title":"Efficacy and safety of orforglipron, an oral small-molecule GLP-1 receptor agonist, on cardiometabolic outcomes: a meta-analysis and systematic review","volume":"12","author":"Alper A","year":"2026","unstructured":"Alper A, Peleg G, Fagin A, Shah P, Chowdhury I, Gonzales A, Faillace R. Efficacy and safety of orforglipron, an oral small-molecule GLP-1 receptor agonist, on cardiometabolic outcomes: a meta-analysis and systematic review. Cardiovasc Diabetol Endocrinol Rep. 2026, 12:9. 10.1186\/s40842-025-00270-4","journal-title":"Cardiovasc Diabetol Endocrinol Rep"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1177\/15209156261420404","article-title":"Efficacy and safety of oral GLP-1 RA Orforglipron on weight and glycemic control according to diabetes status: a systematic review and meta-analysis","author":"Hammad N","year":"2026","unstructured":"Hammad N, Ramadan AM, Nazmy A, Elazab A, Abdelaziz A. Efficacy and safety of oral GLP-1 RA Orforglipron on weight and glycemic control according to diabetes status: a systematic review and meta-analysis. Diabetes Technol Ther. 2026, 10.1177\/15209156261420404","journal-title":"Diabetes Technol Ther"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70742","article-title":"Cardiometabolic profiles of oral and subcutaneous glucagon-like peptide-1 receptor mono-agonists in adults with overweight or obesity: a systematic review and network meta-analysis","author":"Lu Y","year":"2026","unstructured":"Lu Y, Chen J, Guo Y, et al.. Cardiometabolic profiles of oral and subcutaneous glucagon-like peptide-1 receptor mono-agonists in adults with overweight or obesity: a systematic review and network meta-analysis. Diabetes Obes Metab. 2026, 10.1111\/dom.70742","journal-title":"Diabetes Obes Metab"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-026-02357-5","article-title":"Oral glucagon-like peptide-1 receptor agonists for preventing cardiorenal complications","volume":"28","author":"Odeleye V","year":"2026","unstructured":"Odeleye V, Singh N, Gautam S, Shannon E, Bibb WM, McClure M, Paul TK. Oral glucagon-like peptide-1 receptor agonists for preventing cardiorenal complications. Curr Cardiol Rep. 2026, 28:38. 10.1007\/s11886-026-02357-5","journal-title":"Curr Cardiol Rep"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2024.2356254","article-title":"Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now?","volume":"25","author":"Gogineni P","year":"2024","unstructured":"Gogineni P, Melson E, Papamargaritis D, Davies M. Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now?. Expert Opin Pharmacother. 2024, 25:801-18. 10.1080\/14656566.2024.2356254","journal-title":"Expert Opin Pharmacother"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2025.2594493","article-title":"Orforglipron in type 2 diabetes mellitus and obesity: an overview","volume":"18","author":"Panou T","year":"2025","unstructured":"Panou T, Gouveri E, Popovic DS, Papanas N. Orforglipron in type 2 diabetes mellitus and obesity: an overview. Expert Rev Clin Pharmacol. 2025, 18:883-98. 10.1080\/17512433.2025.2594493","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.3390\/scipharm93020026","article-title":"Oral small-molecule GLP-1 receptor agonists: mechanistic insights and emerging therapeutic strategies","volume":"93","author":"Sald\u00edvar-Cer\u00f3n HI","year":"2025","unstructured":"Sald\u00edvar-Cer\u00f3n HI, Vargas-Camacho JA, Le\u00f3n-Cabrera S, Brise\u00f1o-D\u00edaz P, Casta\u00f1eda-Ram\u00edrez AE, Muci\u00f1o-Galicia AE, D\u00edaz-Dom\u00ednguez MR. Oral small-molecule GLP-1 receptor agonists: mechanistic insights and emerging therapeutic strategies. Scientia Pharmaceutica. 2025, 93:26. 10.3390\/scipharm93020026","journal-title":"Scientia Pharmaceutica"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31271-1","article-title":"Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial","volume":"394","author":"Pratley R","year":"2019","unstructured":"Pratley R, Amod A, Hoff ST, et al.. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019, 394:39-50. 10.1016\/S0140-6736(19)31271-1","journal-title":"Lancet"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.2942","article-title":"Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial","volume":"321","author":"Rosenstock J","year":"2019","unstructured":"Rosenstock J, Allison D, Birkenfeld AL, et al.. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial. JAMA. 2019, 321:1466-80. 10.1001\/jama.2019.2942","journal-title":"JAMA"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01185-6","article-title":"Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"402","author":"Knop FK","year":"2023","unstructured":"Knop FK, Aroda VR, Do Vale RD, et al.. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023, 402:705-19. 10.1016\/S0140-6736(23)01185-6","journal-title":"Lancet"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2500969","article-title":"Oral semaglutide at a dose of 25 mg in adults with overweight or obesity","volume":"393","author":"Wharton S","year":"2025","unstructured":"Wharton S, Lingvay I, Bogdanski P, et al.. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. N Engl J Med. 2025, 393:1077-87. 10.1056\/NEJMoa2500969","journal-title":"N Engl J Med"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding JP","year":"2021","unstructured":"Wilding JP, Batterham RL, Calanna S, et al.. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021, 384:989-1002. 10.1056\/NEJMoa2032183","journal-title":"N Engl J Med"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.14493","article-title":"Efficacy and safety of oral small molecule glucagon-like peptide 1 receptor agonist danuglipron for glycemic control among patients with type 2 diabetes: a randomized clinical trial","volume":"6","author":"Saxena AR","year":"2023","unstructured":"Saxena AR, Frias JP, Brown LS, Gorman DN, Vasas S, Tsamandouras N, Birnbaum MJ. Efficacy and safety of oral small molecule glucagon-like peptide 1 receptor agonist danuglipron for glycemic control among patients with type 2 diabetes: a randomized clinical trial. JAMA Netw Open. 2023, 6:e2314493. 10.1001\/jamanetworkopen.2023.14493","journal-title":"JAMA Netw Open"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16534","article-title":"Efficacy and safety of danuglipron (PF-06882961) in adults with obesity: a randomized, placebo-controlled, dose-ranging phase 2b study","volume":"27","author":"Buckeridge C","year":"2025","unstructured":"Buckeridge C, Cobain S, Bays HE, et al.. Efficacy and safety of danuglipron (PF-06882961) in adults with obesity: a randomized, placebo-controlled, dose-ranging phase 2b study. Diabetes Obes Metab. 2025, 27:4915-26. 10.1111\/dom.16534","journal-title":"Diabetes Obes Metab"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/493109-comparative-positioning-of-orforglipron-among-selected-glp-1-receptor-agonist-benchmarks-a-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T13:59:09Z","timestamp":1780495149000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/493109-comparative-positioning-of-orforglipron-among-selected-glp-1-receptor-agonist-benchmarks-a-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":43,"URL":"https:\/\/doi.org\/10.7759\/cureus.110178","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,3]]}}}